vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and TIDEWATER INC (TDW). Click either name above to swap in a different company.
TIDEWATER INC is the larger business by last-quarter revenue ($336.8M vs $177.4M, roughly 1.9× Pacira BioSciences, Inc.). TIDEWATER INC runs the higher net margin — 65.3% vs 1.6%, a 63.6% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -2.4%). Over the past eight quarters, TIDEWATER INC's revenue compounded faster (2.4% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Tidewater, Inc. is a publicly traded international petroleum service company headquartered in Houston, Texas, U.S. It operates a fleet of ships, primarily providing vessels and marine services to the offshore petroleum and offshore wind industries.
PCRX vs TDW — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $336.8M |
| Net Profit | $2.9M | $219.9M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | 19.0% |
| Net Margin | 1.6% | 65.3% |
| Revenue YoY | 5.0% | -2.4% |
| Net Profit YoY | — | 495.8% |
| EPS (diluted) | $0.07 | $4.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $336.8M | ||
| Q3 25 | $179.5M | $341.1M | ||
| Q2 25 | $181.1M | $341.4M | ||
| Q1 25 | $168.9M | $333.4M | ||
| Q4 24 | $187.3M | $345.1M | ||
| Q3 24 | $168.6M | $340.4M | ||
| Q2 24 | $178.0M | $339.2M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $219.9M | ||
| Q3 25 | $5.4M | $-806.0K | ||
| Q2 25 | $-4.8M | $72.9M | ||
| Q1 25 | $4.8M | $42.7M | ||
| Q4 24 | — | $36.9M | ||
| Q3 24 | $-143.5M | $46.4M | ||
| Q2 24 | $18.9M | $50.4M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 19.0% | ||
| Q3 25 | 3.5% | 18.4% | ||
| Q2 25 | 4.7% | 23.7% | ||
| Q1 25 | 1.2% | 22.5% | ||
| Q4 24 | 13.2% | 23.6% | ||
| Q3 24 | -82.8% | 20.6% | ||
| Q2 24 | 15.9% | 23.0% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 65.3% | ||
| Q3 25 | 3.0% | -0.2% | ||
| Q2 25 | -2.7% | 21.4% | ||
| Q1 25 | 2.8% | 12.8% | ||
| Q4 24 | — | 10.7% | ||
| Q3 24 | -85.1% | 13.6% | ||
| Q2 24 | 10.6% | 14.8% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $4.37 | ||
| Q3 25 | $0.12 | $-0.02 | ||
| Q2 25 | $-0.11 | $1.46 | ||
| Q1 25 | $0.10 | $0.83 | ||
| Q4 24 | $0.38 | $0.70 | ||
| Q3 24 | $-3.11 | $0.87 | ||
| Q2 24 | $0.39 | $0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $578.8M |
| Total DebtLower is stronger | — | $670.1M |
| Stockholders' EquityBook value | $653.9M | $1.4B |
| Total Assets | $1.2B | $2.4B |
| Debt / EquityLower = less leverage | — | 0.49× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $578.8M | ||
| Q3 25 | $246.3M | $428.2M | ||
| Q2 25 | $445.9M | $369.4M | ||
| Q1 25 | $493.6M | $341.8M | ||
| Q4 24 | $484.6M | $324.9M | ||
| Q3 24 | $453.8M | $280.8M | ||
| Q2 24 | $404.2M | $315.9M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $670.1M | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $647.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $1.4B | ||
| Q3 25 | $727.2M | $1.1B | ||
| Q2 25 | $757.8M | $1.1B | ||
| Q1 25 | $798.5M | $1.1B | ||
| Q4 24 | $778.3M | $1.1B | ||
| Q3 24 | $749.6M | $1.1B | ||
| Q2 24 | $879.3M | $1.1B |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $2.4B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.5B | $2.1B | ||
| Q1 25 | $1.6B | $2.1B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.5B | $2.0B | ||
| Q2 24 | $1.6B | $2.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 0.49× | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 0.58× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $153.0M |
| Free Cash FlowOCF − Capex | — | $147.8M |
| FCF MarginFCF / Revenue | — | 43.9% |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | — | 0.70× |
| TTM Free Cash FlowTrailing 4 quarters | — | $353.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $153.0M | ||
| Q3 25 | $60.8M | $54.7M | ||
| Q2 25 | $12.0M | $85.4M | ||
| Q1 25 | $35.5M | $86.0M | ||
| Q4 24 | $33.1M | $100.0M | ||
| Q3 24 | $53.9M | $49.0M | ||
| Q2 24 | $53.2M | $78.6M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $147.8M | ||
| Q3 25 | $57.0M | $49.6M | ||
| Q2 25 | $9.3M | $80.2M | ||
| Q1 25 | $26.9M | $75.7M | ||
| Q4 24 | $31.0M | $95.5M | ||
| Q3 24 | $49.8M | $43.3M | ||
| Q2 24 | $51.6M | $72.3M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 43.9% | ||
| Q3 25 | 31.7% | 14.5% | ||
| Q2 25 | 5.1% | 23.5% | ||
| Q1 25 | 15.9% | 22.7% | ||
| Q4 24 | 16.6% | 27.7% | ||
| Q3 24 | 29.6% | 12.7% | ||
| Q2 24 | 29.0% | 21.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.5% | ||
| Q3 25 | 2.2% | 1.5% | ||
| Q2 25 | 1.5% | 1.5% | ||
| Q1 25 | 5.1% | 3.1% | ||
| Q4 24 | 1.1% | 1.3% | ||
| Q3 24 | 2.4% | 1.7% | ||
| Q2 24 | 0.9% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.70× | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | 1.17× | ||
| Q1 25 | 7.37× | 2.02× | ||
| Q4 24 | — | 2.71× | ||
| Q3 24 | — | 1.06× | ||
| Q2 24 | 2.82× | 1.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
TDW
Segment breakdown not available.
